EP1150674A1 - Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation - Google Patents

Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Info

Publication number
EP1150674A1
EP1150674A1 EP00903558A EP00903558A EP1150674A1 EP 1150674 A1 EP1150674 A1 EP 1150674A1 EP 00903558 A EP00903558 A EP 00903558A EP 00903558 A EP00903558 A EP 00903558A EP 1150674 A1 EP1150674 A1 EP 1150674A1
Authority
EP
European Patent Office
Prior art keywords
dihydroxy
hydroxymethylpyrrolidine
hydroxymethyl
hydroxy
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00903558A
Other languages
German (de)
French (fr)
Inventor
Jeppe Sturis
Marit Kristiansen
Christina Bjenning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1150674A1 publication Critical patent/EP1150674A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation.
  • the present invention relates to the use of compounds of the general formula I for the treatment or prophylaxis of obesity or appetite regulation.
  • the present invention also embraces use of glycogen phosphorylase inhibitors for the treatment or prophylaxis of obesity or appetite regulation and methods of using the compounds and their pharmaceutical compositions.
  • Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world. Due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity or appetite regulation.
  • the term obesity implies an excess of adipose tissue.
  • obesity is best viewed as any degree of excess adiposity that imparts a health risk.
  • the cut off between normal and obese individuals can only be approximated, but the health risk imparted by the obesity is probably a continuum with increasing adiposity.
  • the Framingham study demonstrated that a 20% excess over desirable weight clearly imparted a health risk.
  • BMI body mass index
  • the regulation of feeding behaviour is incompletely understood. Certain is that brain neuro- chemicals located in specific hypothalamic nuclei regulate onset and termination of feeding. Several regulatory processes may influence these hypothalamic centres: Metabolic signals such as postprandial increases in plasma glucose and insulin; meal-induced gastric distension is another possible inhibitory factor. Local control by brain neurochemicals and cate- cholamines/beta3-adrenoceptors (inhibits feeding and stimulates energy expenditure). Psychological, social, and genetic factors also influence food intake.
  • initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patient eventually regain their weight.
  • An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today.
  • compositions and methods that are useful for the treatment or prophylaxis of obesity or appetite regulation.
  • One object of the present invention is to provide compounds which can effectively be used for the treatment or prophylaxis of obesity or appetite regulation.
  • Glycogen phosphorylase inhibitors constitute a class of compounds which have use in the treatment of diabetes mellitus.
  • Substituted N-(indole-2-carbonyl)-glycinamides acting as glycogen phosphorylase inhibitors are disclose in PCT-publication No. WO96/39384, WO96/39385 and in EP-A-0 846 464, all hereby incorporated by reference.
  • Piperidine and pyrrolidine compounds acting as glycogen phosphorylase inhibitors are disclose in PCT-publication No. WO 95/24391 , WO 97/09040, WO98/40353 and WO 98/50359, all hereby incorporated by reference.
  • glycogen phosphorylase inhibitor may be used as a compound (active agent) of this invention.
  • Such inhibitors can readily by determined by those skilled in the art.
  • Phosphorylase can either be purchased from Sigma or extracted from rat livers according to Stalmans et. al. (Eur.J.Bio-chem. 49 (1974), 415). The activity of phosphorylase can be de- termined as described by Bergmeyer (1983; in: Meth. of Enzymatic Analysis, 2, 293-295, Weinheim, (ed.) Verlag Chemie).
  • a compound is considered to be a potent glycogen phosphorylase inhibitor if the IC50 value is less than 10 ⁇ M.
  • glycogen phosphorylase inhibitors are described above, however, other glycogen phosphorylase inhibitors will be known to those skilled in the art, such as 1-[N-(5-chloroindole-2-carbonyl)-3-(4-fluorophenyl)- L-Alanyl]-4-hydroxypiperidine and (3R,4R,5R)-5-hydroxymethyl-3,4-piperidinediol.
  • the present invention is based in part on the discovery that a representative glycogen phosphorylase inhibitor, 2-alkylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine is effective in appetite regulation and against obesity, in Sprague Dawley rats and in Zucker Diabetic Fatty (ZDF) rats.
  • ZDF rats are generally recognised models of hyperphagia, obesity and diabetes.
  • glycogen phosphorylase inhibitors and the 2-alkylpyrrolidine of formula I are useful as therapeutic appetite regulation agents and therapeutic agent against obesity in mammals, including primates such as humans.
  • the present invention is furthermore useful in treatment or prophylaxes of diseases were lowering of the lipid content in the blood is beneficial such as dyslipidemia, hypertriglyc- eridemia, hyperlipidemia, hyperlipoproteinaemia, cardiovascular diseases and hypertension.
  • the present invention provides the use of a compound of the general formula (I)
  • R ' is hydrogen, acyl, alkene, cycloalkyl or alkyl which optionally is substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, halogen, cycloalkyl, optionally substituted phenyl or alkoxycarbonyl, R 2 is hydrogen or alkyl,
  • R and R4 which are the same or different, independent of each other, is hydrogen, halogen, hydroxy, mercapto or amino which is optionally substituted with alkyl or aralkyl, and
  • R ⁇ is alkyl substituted with hydroxy, halogen, amino, N-alkylamino, N,N-dialkylamino or mercapto, or pharmaceutically acceptable salts or hydrates thereof including any of the optical isomers or mixtures thereof, for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
  • alkyl when used alone or in combination with another moiety, is a straight or branched saturated hydrocarbon chain group which preferably contains not more than 8 carbon atoms, more preferred not more than 4 carbon atoms.
  • Especially preferred alkyl groups are methyl, ethyl, propyl and isopropyl.
  • halogen refers to chloro, bromo or fluoro, preferably fluoro.
  • N-alkylamino is N-methylamino.
  • N,N-dialkylamino is N,N-dimethyl-amino.
  • acyl refers to carbonyl substituted with hydrogen, alkyl or phenyl.
  • cycloalkyl preferably contains 3-7 carbon atoms, more prefered 3-6 carbon atoms.
  • Alkoxy preferably is methoxy or ethoxy.
  • Alkoxycarbonyl preferably is methoxycarbonyl or ethoxycarbonyl.
  • Aralkyl preferably is benzyl.
  • Trifluoroalkyl preferably is trifluoromethyl or 2,2,2-trifluoroethyl.
  • Alkene preferably contains not more than 8 carbon atoms and preferably is allyl.
  • the term "one or more" substituents preferably is 1-3 substituents, most preferred 1.
  • compound of formula (I) contains at least 2 hydroxy groups in another embodiment formula (I) contains at least 3 hydroxy goups.
  • a subgroup of compounds to be used according to this invention are compounds of formula wherein the two substituent designated by the symbols R3 and R5 are situated at the same side of the plane formed by the 5 membered nitrogen containing ring, and R4 is situated at the opposite side of the plane formed by the 5 membered nitrogen containing ring.
  • Examples of compounds to be used according to this invention are compounds of formula I wherein R1 is alkyl which optionally is substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, alkoxycarbonyl, cycloalkyl or optionally substituted phenyl.
  • R1 is hydrogen
  • R1 is phenylalkyl wherein the phenyl moiety optionally is substituted with one or more of the following groups: halogen, hydroxy, alkoxy, trifluoromethyl or cyano.
  • R3 and R4 are both hydroxy.
  • R5 is hydroxyalkyl, such as hydroxy methyl.
  • Another subgroup of compounds to be used according to this invention are compounds of formula I wherein R3 and R4 each are hydroxy, and R5 is hydroxymethyl.
  • the compounds of formula I may be presented as a mixture of isomers which, if desired, may be resolved into the individual pure enantiomers. This resolution may conveniently be performed by fractional crystallisation from various solvents, of the salts of compounds of the formula I with optical active acids or by other methods known per se, for example, chiral column chromatography. This invention includes all isomers, whether resolved or mixtures thereof.
  • Examples of compounds to be used according to this invention are 3,4-dihydroxy-2- hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, 1- cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -propylpyrrolidine, 1 -butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1 -(2,2,2-trifluoroethyl)pyrrolidine, 1 -benzyl-3,4-dihydroxy-2- hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1 -(2-hydroxyethyl)pyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1-(1 ,3-dihydroxyprop-2-yl)pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -(2, 3-dihydroxyprop-1 -yl)pyrrolidine, 1 -(2-amino
  • the compound of general formula (I) is (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrochloride or (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrobromide.
  • the present invention relates to (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrobromide.
  • the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for lowering of food intake.
  • the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake.
  • the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake.
  • the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for lowering of food intake of food with a high fat content.
  • the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake of food with a high fat content.
  • the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake of food with a high fat content.
  • the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
  • the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
  • the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
  • the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
  • the present invention relates to the use of a glycogen phosphorylase inhibitor with an IC50 value less than 10 ⁇ M.
  • the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a compound of formula I defined in anyone of the preceding claims to a patient in need of such a treatment.
  • the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a glycogen phosphorylase inhibitor to a patient in need of such a treatment.
  • the compounds of formula I are prepared by methods known per se by the skilled art worker, for example as described in the following.
  • the compounds of formula I can be prepared by joining the C-1 and C-4 of xylose together with nitrogen to form the pyrrolidine ring as described in Tetrahedron 42 (1986), 5685 et seq, hereby incorporated by reference.
  • a variety of functional groups can be introduced in the compounds prepared as out-lined above by methods well known to those skilled in the art.
  • R2, R3, R4, and R5 are as defined in the claims below, with an aldehyde in presence of a reducing agent among which sodium cyanoborohydride is preferred, to form a compound of formula I.
  • the leaving group, Y may be any suitable leaving group as for example halogen.
  • R1 either is as defined in the claims below or is a readily removable protection group, i.e. benzyl
  • R2 is as defined in the claims below and R3 and R4 are protected hy- droxy, i.e. benzyloxy, with a halogenating agent such as thionyl chloride, thionyl bromide, or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of formula I, wherein R1 , R3, and R4 are as defined in the claims below, and R5 is methyl substituted with halogen.
  • a halogenating agent such as thionyl chloride, thionyl bromide, or diethylaminosulfur trifluoride (DAST)
  • R1 either is as defined in the claims below or is a readily removable protection group, i.e. benzyl
  • R2 is as defined in the claims below
  • R3 and R4 are protected hydroxy, i.e. benzyloxy
  • X is a leaving group, with a compound of the general formula NHR6R7, wherein the two substituents R6 and R7 may both be alkyl, or one is alkyl and the other is hydrogen or together with NH R6 and R7 form phthalimide, and subsequent removal of the protection groups to form the compounds of formula I, wherein R1 , R2, R3, and R4 are as defined in the claims below, and R5 is methyl substituted with amino, N-alkylamino, or N,N- dialkyiamino.
  • the leaving group, X may be any suitable leaving group as for example halogen.
  • R1 and R2 are as defined in the claims below, and one or two of the groups R3 and R4 is hydroxy and the remaining is protected hydroxy, i.e. benzyl, R5 is as defined in the claims below or is a corresponding protected group, with a halogenating agent such as thionyl chloride, thionyl bromide or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of the formula I, wherein R1 , R2 and R5 are as defined in the claims below, and R3 and R4 are hydroxy or halogen, but not more than one of R3 and R4 is hydroxy.
  • a halogenating agent such as thionyl chloride, thionyl bromide or diethylaminosulfur trifluoride (DAST)
  • Examples of pharmaceutically acceptable salts are acid addition salts with non-toxic acids, either inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid
  • organic acids such as formic acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.
  • 2-alkyl-pyrrolidines of formula I and their salts are useful within human and veterinary medicine, for example, in the treatment of patients suffering from obesity.
  • 2-alkyl-pyrrolidines of formula I and their pharmaceutically acceptable salts are formulated with a pharmaceutically acceptable carrier to provide a medicament for par- enteral, oral, nasal, rectal, subdermal or intradermal or transdermal, pulmonal, buccal administration according to conventional methods.
  • Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc.
  • the active compound of formula I is prepared in a form suitable for oral administration, such as a tablet or capsule.
  • a pharmaceutically ac- ceptable salt of the compound of formula I is combined with a carrier and moulded into a tablet.
  • Suitable carriers include starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like.
  • Such compositions may further include one or more auxiliary substances, such as wetting agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
  • compositions containing a compound of formula I may be administered one or more times per day or week.
  • An effective amount of such a pharmaceutical composition is the amount that provides a clinically significant effect against obesity or appetite regulation. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art.
  • a convenient daily dosage can be less than about 1g, preferably in the range around 50-1000mg.
  • Test 2 Twenty-eight genetically obese male Zucker fatty (fa/fa) rates are bought from Charles River, Germany. The animals are housed in metal hanging cages in groups of 3 or 4 per cage and have ad libitum access to food and water for one week of acclimation. Room temperature is maintained at 21+ 0.5°C with a relative humidity of 40%. The photope od in the room is 12 hours light and 12 hours dark.
  • test compounds After a one week acclimation period dosing with the test compounds is initiated.
  • the amount of compound administered is from 0.001 to 100 mg/day and the period of administration is 1 month.
  • the compound is given by gavage twice daily.
  • the food consumption is measured daily and the animals are weighed two times per week during the treatment period.
  • Test 4 The same procedure is used as in Test 2, except the period of administration is 3 months. Test 4
  • Test 5 Between 3 and 20 obese (according to the criteria mentioned above) women are administered a compound of the present invention.
  • the amount of compound administered is from 0.1 to 4000 mg/day, and the period of treatment is 6 months.
  • the women are observed during the period of administration, and up to 3 months after discon- tinuance of administration, for effects on their obesity.
  • Twenty male Sprague-Dawley rats are allocated into two groups and are presented with a high-fat diet ad libitum. After a two week acclimation period, the animals are presented with an isocaloric, high-carbohydrate diet as well as. During the following two baseline weeks, the consumption of the two types of foods is measured on a daily basis. Hereafter, one group is injected intraperitoneally twice daily for seven days with 85 mg/kg/dose compound 1 , the other group is injected intraperitoneally twice daily with vehicle. The consumption of the two types of foods and the change in body weight is measured and compared between the groups and between treatment and baseline periods. Based on the results in the previous example, treatment with compound 1 will cause the animals to eat less high fat food, rela- tively more high carbohydrate food, fewer total calories as well as a reduction in body weight, all relative to the vehicle treated group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of compounds of general formula (I) for the treatment or prophylaxis of obesity or appetite regulation. The present invention also embraces use of glycogen phosphorylase inhibitors for the treatment or prophylaxis of obesity or appetite regulation and methods of using the compounds and their pharmaceutical compositions.

Description

Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation.
FIELD OF THIS INVENTION The present invention relates to the use of compounds of the general formula I for the treatment or prophylaxis of obesity or appetite regulation. The present invention also embraces use of glycogen phosphorylase inhibitors for the treatment or prophylaxis of obesity or appetite regulation and methods of using the compounds and their pharmaceutical compositions.
BACKGROUND OF THIS INVENTION
Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world. Due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity or appetite regulation.
Exercise, diet modification and food restriction will reduce body weight but for most patients, this is not feasible. Pharmacological treatment available up to date only consists of Sibutra- mine (acting via serotonergic mechanisms, Knoll Pharm) and Orlistat (reducing fat uptake from the gut, Roche Pharm) neither reducing body weight effectively nor acceptably
The term obesity implies an excess of adipose tissue. In this context obesity is best viewed as any degree of excess adiposity that imparts a health risk. The cut off between normal and obese individuals can only be approximated, but the health risk imparted by the obesity is probably a continuum with increasing adiposity. The Framingham study demonstrated that a 20% excess over desirable weight clearly imparted a health risk. (Mann GV N.Engl.J.Med 291 :226, 1974). In the United States a National Institutes of Health consensus panel on obesity agreed that a 20% increase in relative weight or a body mass index (BMI = body weight in kilograms divided by the square of the height in meters) above the 85th percentile for young adults constitutes a health risk. By the use of these criteria 20 to 30 percent of adult men and 30 to 40 percent of adult women in the United States are obese. (NIH, Ann Intern Med 103:147, 1985).
Indeed, the prevalence of obesity has increased with 100% in most western countries the last 20 years, and this is very serious because even mild obesity increases the risk for premature death, type 2 diabetes, coronary heart disease, hypertension, atherosclerosis, sleep apnea and respiratory problems, osteoarthritis gallbladder disease and certain types of can- cer (endomet al, breast, prostate and colon. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority. When energy intake exceeds expenditure, the excess calories are stored in adipose tissue, and if this net positive balance is prolonged, obesity results, i.e. there are two components to weight balance, and an abnormality on either side (intake or expenditure) can lead to obesity.
The regulation of feeding behaviour is incompletely understood. Certain is that brain neuro- chemicals located in specific hypothalamic nuclei regulate onset and termination of feeding. Several regulatory processes may influence these hypothalamic centres: Metabolic signals such as postprandial increases in plasma glucose and insulin; meal-induced gastric distension is another possible inhibitory factor. Local control by brain neurochemicals and cate- cholamines/beta3-adrenoceptors (inhibits feeding and stimulates energy expenditure). Psychological, social, and genetic factors also influence food intake.
At present a variety of techniques are available to effect initial weight loss. Unfortunately, initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patient eventually regain their weight. An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today.
Thus there remains today a need in the art for compositions and methods that are useful for the treatment or prophylaxis of obesity or appetite regulation.
One object of the present invention is to provide compounds which can effectively be used for the treatment or prophylaxis of obesity or appetite regulation.
BRIEF DESCRIPTION OF THIS INVENTION
Surprisingly, it has now turned out that administration of compounds that are a glycogen phosphorylase inhibitors has an effect on food intake, specifically the intake of food with a high content of fat, satiety, appetite and weight disorders. Based on these observations it is now possible to provide a medicament and a method for the treatment or prophylaxis of obesity or appetite regulation.
DETAILED DESCRIPTION OF THIS INVENTION
Glycogen phosphorylase inhibitors constitute a class of compounds which have use in the treatment of diabetes mellitus. Substituted N-(indole-2-carbonyl)-glycinamides acting as glycogen phosphorylase inhibitors are disclose in PCT-publication No. WO96/39384, WO96/39385 and in EP-A-0 846 464, all hereby incorporated by reference. Piperidine and pyrrolidine compounds acting as glycogen phosphorylase inhibitors are disclose in PCT-publication No. WO 95/24391 , WO 97/09040, WO98/40353 and WO 98/50359, all hereby incorporated by reference.
International patent application having publication No. WO 97/09040 relates to (2R,3R,4R)- 3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-alkylpyrrolidines and their use for treatment of diabetes.
Any glycogen phosphorylase inhibitor may be used as a compound (active agent) of this invention. Such inhibitors can readily by determined by those skilled in the art. Phosphorylase can either be purchased from Sigma or extracted from rat livers according to Stalmans et. al. (Eur.J.Bio-chem. 49 (1974), 415). The activity of phosphorylase can be de- termined as described by Bergmeyer (1983; in: Meth. of Enzymatic Analysis, 2, 293-295, Weinheim, (ed.) Verlag Chemie). A compound is considered to be a potent glycogen phosphorylase inhibitor if the IC50 value is less than 10 μM. A variety of glycogen phosphorylase inhibitors are described above, however, other glycogen phosphorylase inhibitors will be known to those skilled in the art, such as 1-[N-(5-chloroindole-2-carbonyl)-3-(4-fluorophenyl)- L-Alanyl]-4-hydroxypiperidine and (3R,4R,5R)-5-hydroxymethyl-3,4-piperidinediol.
The present invention is based in part on the discovery that a representative glycogen phosphorylase inhibitor, 2-alkylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine is effective in appetite regulation and against obesity, in Sprague Dawley rats and in Zucker Diabetic Fatty (ZDF) rats. ZDF rats are generally recognised models of hyperphagia, obesity and diabetes.
These data thus indicate that glycogen phosphorylase inhibitors and the 2-alkylpyrrolidine of formula I are useful as therapeutic appetite regulation agents and therapeutic agent against obesity in mammals, including primates such as humans.
The present invention is furthermore useful in treatment or prophylaxes of diseases were lowering of the lipid content in the blood is beneficial such as dyslipidemia, hypertriglyc- eridemia, hyperlipidemia, hyperlipoproteinaemia, cardiovascular diseases and hypertension.
The present invention provides the use of a compound of the general formula (I)
R1
(i)
wherein R ' is hydrogen, acyl, alkene, cycloalkyl or alkyl which optionally is substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, halogen, cycloalkyl, optionally substituted phenyl or alkoxycarbonyl, R2 is hydrogen or alkyl,
R and R4, which are the same or different, independent of each other, is hydrogen, halogen, hydroxy, mercapto or amino which is optionally substituted with alkyl or aralkyl, and
R^ is alkyl substituted with hydroxy, halogen, amino, N-alkylamino, N,N-dialkylamino or mercapto, or pharmaceutically acceptable salts or hydrates thereof including any of the optical isomers or mixtures thereof, for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
Hereinafter, the term alkyl, when used alone or in combination with another moiety, is a straight or branched saturated hydrocarbon chain group which preferably contains not more than 8 carbon atoms, more preferred not more than 4 carbon atoms. Especially preferred alkyl groups are methyl, ethyl, propyl and isopropyl.
The term halogen as used herein refers to chloro, bromo or fluoro, preferably fluoro. Prefera- bly, N-alkylamino is N-methylamino. Preferably, N,N-dialkylamino is N,N-dimethyl-amino. The term acyl as used herein refers to carbonyl substituted with hydrogen, alkyl or phenyl.
Herein, cycloalkyl preferably contains 3-7 carbon atoms, more prefered 3-6 carbon atoms.
Alkoxy preferably is methoxy or ethoxy. Alkoxycarbonyl preferably is methoxycarbonyl or ethoxycarbonyl. Aralkyl preferably is benzyl. Trifluoroalkyl preferably is trifluoromethyl or 2,2,2-trifluoroethyl. Alkene preferably contains not more than 8 carbon atoms and preferably is allyl. The term "one or more" substituents preferably is 1-3 substituents, most preferred 1.
In one embodiment compound of formula (I) contains at least 2 hydroxy groups in another embodiment formula (I) contains at least 3 hydroxy goups. A subgroup of compounds to be used according to this invention are compounds of formula wherein the two substituent designated by the symbols R3 and R5 are situated at the same side of the plane formed by the 5 membered nitrogen containing ring, and R4 is situated at the opposite side of the plane formed by the 5 membered nitrogen containing ring.
Examples of compounds to be used according to this invention are compounds of formula I wherein R1 is alkyl which optionally is substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, alkoxycarbonyl, cycloalkyl or optionally substituted phenyl.
In one embodiment R1 is hydrogen.
Another example of compounds to be used according to this invention are compounds of formula I wherein R1 is phenylalkyl wherein the phenyl moiety optionally is substituted with one or more of the following groups: halogen, hydroxy, alkoxy, trifluoromethyl or cyano.
In another embodiment R3 and R4 are both hydroxy.
In still another embodiment R5 is hydroxyalkyl, such as hydroxy methyl.
Another subgroup of compounds to be used according to this invention are compounds of formula I wherein R3 and R4 each are hydroxy, and R5 is hydroxymethyl.
Any possible combination of two or more of the embodiment described herein is comprised within the scope of the present invention.
The compounds of formula I may be presented as a mixture of isomers which, if desired, may be resolved into the individual pure enantiomers. This resolution may conveniently be performed by fractional crystallisation from various solvents, of the salts of compounds of the formula I with optical active acids or by other methods known per se, for example, chiral column chromatography. This invention includes all isomers, whether resolved or mixtures thereof.
Examples of compounds to be used according to this invention are 3,4-dihydroxy-2- hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, 1- cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -propylpyrrolidine, 1 -butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1 -(2,2,2-trifluoroethyl)pyrrolidine, 1 -benzyl-3,4-dihydroxy-2- hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1 -(2-hydroxyethyl)pyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1-(1 ,3-dihydroxyprop-2-yl)pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -(2, 3-dihydroxyprop-1 -yl)pyrrolidine, 1 -(2-aminoethyl)-3,4-dihydroxy-2- hydroxymethylpyrrolidine and salts and hydrates thereof, preferably (2R,3R,4R)-3,4- dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1- methylpyrrolidine, (2R,3R,4R)-1-cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-di-hydroxy-2-hydroxymethyl-1 -propylpyrrolidine, (2R,3R,4R)-1 -butyl-3,4- dihydroxy-2-hydroxymethylpyrroIidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1 -(2,2,2- trifluoroethyl)pyrrolidine, (2R,3R,4R)-1-benzyl-3,4-dihydroxy-2-hydroxy-methylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine, (2R,3R,4R)-3,4- dihydroxy-2-hydroxymethyl-1 -(2,3-di-hydroxy-prop-1 -yl)pyrrolidine, (2R,3R,4R)-3,4- dihydroxy-2-hydroxymethyl-1 -(1 ,3-dihydroxy-prop-2-yl)pyrrolidine, (2R,3R,4R)-1 -(2- aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1 -methylpyrrolidine, (2S,3S,4S)-1-cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4- dihydroxy-2-hydroxy-methyl-1 -propyl-pyrrolidine, (2S,3S,4S)-1 -butyl-3,4-dihydroxy-2- hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoro- ethyl)pyrrolidine, (2S,3S,4S)-1 -benzyl-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine,
(2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine, (2S,3S,4S)-3,4- dihydroxy-2-hydroxymethyl-1 -(2,3-dihydroxyprop-1 -yl)pyrrolidine, (2S,3S,4S)-3,4-dihydroxy- 2-hydroxymethyl-1-(1 ,3-dihydroxyprop-2-yl)pyrrolidine, (2S,3S,4S)-1-(2-aminoethyl)-3,4- dihydroxy-2-hydroxymethylpyrrolidine and salts and hydrates thereof.
In one embodiment the compound of general formula (I) is (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrochloride or (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrobromide.
In a further aspect, the present invention relates to (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, hydrobromide.
In a further aspect, the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for lowering of food intake. In one embodiment, the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake.
In another embodiment, the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake.
In a further aspect, the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for lowering of food intake of food with a high fat content.
In one embodiment, the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake of food with a high fat content.
In another embodiment, the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake of food with a high fat content.
In a further aspect, the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
In one embodiment, the present invention relates to the use of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
In another embodiment, the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
In still a further aspect, the present invention relates to the use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
In one embodiment, the present invention relates to the use of a glycogen phosphorylase inhibitor with an IC50 value less than 10μM. In still a further aspect, the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a compound of formula I defined in anyone of the preceding claims to a patient in need of such a treatment. In still a further aspect, the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a glycogen phosphorylase inhibitor to a patient in need of such a treatment.
Generally, the compounds of formula I are prepared by methods known per se by the skilled art worker, for example as described in the following. The compounds of formula I can be prepared by joining the C-1 and C-4 of xylose together with nitrogen to form the pyrrolidine ring as described in Tetrahedron 42 (1986), 5685 et seq, hereby incorporated by reference. A variety of functional groups can be introduced in the compounds prepared as out-lined above by methods well known to those skilled in the art.
More specifically, the compounds of formula I can be prepared as follows:
a) Reacting a compound of the general formula II
(ll) H
wherein R2, R3, R4, and R5 are as defined in the claims below, with an aldehyde in presence of a reducing agent among which sodium cyanoborohydride is preferred, to form a compound of formula I.
b) Reacting a compound of the general formula II
(M) H wherein R2, R3, R4, and R5 are as defined in the claims below, with a compound of the general formula R1Y, wherein R1 is as defined in the claims below, and Y is a leaving group, to form a compound of formula I. The reaction is carried out under alkaline conditions, i.e. in the presence of a base.
The leaving group, Y, may be any suitable leaving group as for example halogen.
c) Reacting a compound of the general formula III
R1
(IN)
wherein R1 either is as defined in the claims below or is a readily removable protection group, i.e. benzyl, R2 is as defined in the claims below and R3 and R4 are protected hy- droxy, i.e. benzyloxy, with a halogenating agent such as thionyl chloride, thionyl bromide, or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of formula I, wherein R1 , R3, and R4 are as defined in the claims below, and R5 is methyl substituted with halogen.
d) Reacting a compound of the general formula IV
wherein R1 either is as defined in the claims below or is a readily removable protection group, i.e. benzyl, R2 is as defined in the claims below, R3 and R4 are protected hydroxy, i.e. benzyloxy, and X is a leaving group, with a compound of the general formula NHR6R7, wherein the two substituents R6 and R7 may both be alkyl, or one is alkyl and the other is hydrogen or together with NH R6 and R7 form phthalimide, and subsequent removal of the protection groups to form the compounds of formula I, wherein R1 , R2, R3, and R4 are as defined in the claims below, and R5 is methyl substituted with amino, N-alkylamino, or N,N- dialkyiamino.
The leaving group, X, may be any suitable leaving group as for example halogen.
e) Reacting a compound of the general formula I
R1
(I)
wherein R1 and R2 are as defined in the claims below, and one or two of the groups R3 and R4 is hydroxy and the remaining is protected hydroxy, i.e. benzyl, R5 is as defined in the claims below or is a corresponding protected group, with a halogenating agent such as thionyl chloride, thionyl bromide or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of the formula I, wherein R1 , R2 and R5 are as defined in the claims below, and R3 and R4 are hydroxy or halogen, but not more than one of R3 and R4 is hydroxy.
PHARMACEUTICAL COMPOSITION
Examples of pharmaceutically acceptable salts are acid addition salts with non-toxic acids, either inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid, citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.
2-alkyl-pyrrolidines of formula I and their salts are useful within human and veterinary medicine, for example, in the treatment of patients suffering from obesity. For use within the pre- sent invention, 2-alkyl-pyrrolidines of formula I and their pharmaceutically acceptable salts are formulated with a pharmaceutically acceptable carrier to provide a medicament for par- enteral, oral, nasal, rectal, subdermal or intradermal or transdermal, pulmonal, buccal administration according to conventional methods. Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, suppositories, liposomes, transdermal patches, controlled release, dermal implants, tablets, etc. One skilled in this art may formulate the compounds of formula I in an appropriate manner, and in accordance with accepted prac- tices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990.
Oral administration is preferred. Thus, the active compound of formula I is prepared in a form suitable for oral administration, such as a tablet or capsule. Typically, a pharmaceutically ac- ceptable salt of the compound of formula I is combined with a carrier and moulded into a tablet. Suitable carriers in this regard include starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like. Such compositions may further include one or more auxiliary substances, such as wetting agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
Pharmaceutical compositions containing a compound of formula I may be administered one or more times per day or week. An effective amount of such a pharmaceutical composition is the amount that provides a clinically significant effect against obesity or appetite regulation. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art. A convenient daily dosage can be less than about 1g, preferably in the range around 50-1000mg.
The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection.
The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
EXAMPLES Example 1
Test l
The effects of oral administration of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, herein referred to as compound 1 , on food intake and weight gain have been examined in the male Zucker diabetic fatty (ZDF) rat, a genetic model of obesity, insulin resistance and Type 2 diabetes. Twenty male ZDF rats were acquired from Genetic Models Inc., Indianapolis Indiana, USA. At ten weeks of age the animals were orally dosed with either compound 1 (n=10) or vehicle (n=10). Compound was administered in the drinking water to which the animals had continuous access. Animals were caged in groups of five, i.e. two cages were treated with compound 1 and two cages were treated with vehicle.
Body weight (g) Unfasted blood glucose (mM)
Compound 1 group (n=10) 332±19 14.2±3.8
Vehicle group (n=10) 336±17 14.2±3.6
Table 1. Body weight and unfasted glucose in the two groups prior to administration of any compound 1. Data are expressed as mean±SD.
Initial body weights and unfasted glucose levels were not different between the two groups (Table 1). During seven days of therapy (mean drug administration in the compound 1 treated group being 171 mg/kg/24h), food intake was markedly reduced in the drug-treated group.
Thus, the average daily food intake during the seven days for all animals in each group was
18% lower in the group treated with compound 1 than in the vehicle treated group (160+/-10 vs
196+/-13 g chow/cage/24h, p<0.05 by repeated measures ANOVA). The lower food intake was associated with a significantly smaller increase in body weight in the animals treated with compound 1 than in vehicle treated animals (28.1 ±4.5 g/rat vs 32.9±3.4 g/rat, p<0.02). No deleterious toxicological effects were observed in this study.
Test 2 Twenty-eight genetically obese male Zucker fatty (fa/fa) rates are bought from Charles River, Germany. The animals are housed in metal hanging cages in groups of 3 or 4 per cage and have ad libitum access to food and water for one week of acclimation. Room temperature is maintained at 21+ 0.5°C with a relative humidity of 40%. The photope od in the room is 12 hours light and 12 hours dark.
After a one week acclimation period dosing with the test compounds is initiated. The amount of compound administered is from 0.001 to 100 mg/day and the period of administration is 1 month. The compound is given by gavage twice daily. The food consumption is measured daily and the animals are weighed two times per week during the treatment period.
Test 3
The same procedure is used as in Test 2, except the period of administration is 3 months. Test 4
The same procedure is used as in Test 2, except the period of administration is 6 months.
Test 5 Between 3 and 20 obese (according to the criteria mentioned above) women are administered a compound of the present invention. The amount of compound administered is from 0.1 to 4000 mg/day, and the period of treatment is 6 months.
The women are observed during the period of administration, and up to 3 months after discon- tinuance of administration, for effects on their obesity.
Test 6
The same procedure is used as in Test 5, except the period of administration is 1 year.
Test 7
The same procedure is used as in Test 5, except between 3 and 20 obese males are used.
Test 8
The same procedure is used as in Test 7, except the period of administration is 1 year.
Example 2
Test 9
The effects of intraperitoneally (i.p.) administration of (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, herein referred to as compound 1 , on food intake and weight gain have been examined in the male Sprague-Dawley rats.
Thirty male Sprague-Dawley rats aged 10 week were allocated into four groups: group A (n=5) and group B (n=10) were placed on a high-fat diet and group C (n=5) and group D (n=10) were placed on a high-carbohydrate diet (High-fat diet Bio-Serv, diet#F3730, 40% fat; 36% carbohydrates; High-carbohydrate diet Bio-Serv, diet#F3729 4.9% fat, 57% carbohy- drates). After a four-day baseline period, groups A and C were administrated intraperitoneal (i.p.) twice daily for seven days with 85 mg/kg/dose of compound 1 , while groups B and D were administrated intraperitoneal twice daily for seven days with vehicle. During the treatment period, food intake was significantly lower during compound 1 administration in group A compared to group B while there was no difference in food intake between group C and D. Accordingly, a significantly smaller increase in body weight was observed in group A vs Group B, while no difference in body weight increase was observed between groups C and D. In the tables below food intake and body weights on the final day of treatment are summarized (mean+SEM).
*not significant vs Group D
These data strongly imply that if animals are given a choice of high-fat and high- carbohydrate foods, compound 1 cause a shift in food preference, resulting in a reduced fat intake, a relatively increased carbohydrate intake, and an overall reduction in caloric intake and a lower body weight compared to vehicle. To show this experimentally, the following experiment can be performed:
Test 10:
Twenty male Sprague-Dawley rats are allocated into two groups and are presented with a high-fat diet ad libitum. After a two week acclimation period, the animals are presented with an isocaloric, high-carbohydrate diet as well as. During the following two baseline weeks, the consumption of the two types of foods is measured on a daily basis. Hereafter, one group is injected intraperitoneally twice daily for seven days with 85 mg/kg/dose compound 1 , the other group is injected intraperitoneally twice daily with vehicle. The consumption of the two types of foods and the change in body weight is measured and compared between the groups and between treatment and baseline periods. Based on the results in the previous example, treatment with compound 1 will cause the animals to eat less high fat food, rela- tively more high carbohydrate food, fewer total calories as well as a reduction in body weight, all relative to the vehicle treated group.

Claims

1. The use of a compound of the general formula (I)
R1
(l)
wherein R1 is hydrogen, acyl, alkene, cycloalkyl or alkyl which optionally is substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, halogen, cycloalkyl, optionally substituted phenyl or alkoxycarbonyl, R2 is hydrogen or alkyl,
R^ and R4, which are the same or different, independent of each other, is hydrogen, halogen, hydroxy, mercapto or amino which is optionally substituted with alkyl or aralkyl, and R^ is alkyl substituted with hydroxy, halogen, amino, N-alkylamino, N,N-dialkylamino or mercapto, or pharmaceutically acceptable salts or hydrates thereof including any of the optical isomers or mixtures thereof, for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
2. The use, according to claim 1 , wherein the compound of formula (I) contains at least
2 hydroxy groups.
3. The use, according to claim 1 , wherein the compound of formula (I) contains at least
3 hydroxy groups.
4. The use, according to any one of the claims 1 to 3, wherein R^ and R5 are situated at the same side of the plane formed by the 5-membered nitrogen containing ring, and R4 is situated at the opposite side of the plane formed by the 5-membered nitrogen containing ring.
5. The use, according to any one of the claims 1-4, wherein R^ represents hydrogen, acyl or alkyl which is optionally substituted with one or more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, phenyl or alkoxycarbonyl.
6. The use, according to any one of the claims 1 to 5, wherein R-' is methyl.
7. The use, according to any of one of the claims 1 to 4, wherein R1 is hydrogen.
8. The use, according to any one of the claims 1 to 7, wherein the optionally substituted phenyl group is phenyl substituted with one or more of the following groups: halogen, hydroxy, alkoxy, trifluoroalkyl or cyano.
9. The use, according to any one of the claims 1 to 8, wherein R2 is methyl.
10. The use, according to any one of the claims 1 to 8, wherein R2 is hydrogen.
11. The use, according to any one of the claims 1 to10, wherein R^ is hydrogen, hydroxy, halogen or amino.
12. The use, according to any one of the claims 1-11 , wherein R^ is hydroxy or halogen, preferably fluoro.
13. The use, according to any one of the claims 1-12, wherein R^ is hydroxy.
14. The use, according to any one of the claims 1-13, wherein R4 is hydrogen, hydroxy, halogen or amino.
15. The use, according to any one of the claims 1-14, wherein R4 is hydroxy or halogen preferably fluoro.
16. The use, according to any one of the claims 1-15, wherein R4 is hydroxy.
17. The use, according to any one of the claims 1-16, wherein in the compound of formula I R^ is hydroxyalkyl.
18. The use, according to any one of the claims 1-17, wherein R^ is hydroxymethyl, hydroxyethyl or hydroxypropyl, preferably hydroxymethyl.
19. The use, according to any one of the claims 1-16, wherein R^ is hydroxymethyl.
20. The use according to claim 1 , wherein the compound of general formula (I) is 3,4- dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1 -methylpyrrolidine, 1- cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -propylpyrrolidine, 1 -butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1 -(2,2,2-trifluoroethyl)-pyrrolidine, 1 -benzyl-3,4-dihydroxy-2- hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine, 3,4- dihydroxy-2-hydroxymethyl-1-(1 ,3-dihydroxyprop-2-yl)pyrrolidine, 3,4-dihydroxy-2- hydroxymethyl-1 -(2,3-dihydroxyprop-1 -yl)pyrrolidine, 1 -(2-aminoethyl)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, preferably 3,4-dihydroxy-2-hydroxymethylpyrrolidine and any of the optical isomers thereof.
21. The use according to claim 1 , wherein the compound of general formula (I) is (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethyl-1 -methylpyrrolidine, (2R,3R,4R)-1 -cyclopropylmethyl-3,4-dihydroxy-2- hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1 -propylpyrrolidine, (2R,3R,4R)-1 -butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethyl-1-(2,2,2-trifluoroethyl)-pyrrolidine,
(2R,3R,4R)-1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2- hydroxymethyl-1 -(2-hydroxyethyl)pyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1 - (2,3-dihydroxyprop-1-yl)-pyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(1 ,3- dihydroxyprop-2-yl)pyrrolidine, (2R,3R,4R)-1 -(2-aminoethyl)-3,4-dihydroxy-2- hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)- 3,4-di-hydroxy-2-hydroxymethyl-1 -methylpyrrolidine, (2S,3S,4S)-1 -cyclopropylmethyl-3,4- dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-propyl- pyrrolidine, (2S,3S,4S)-1 -butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4- dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoro-ethyl)pyrrolidine, (2S,3S,4S)-1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-di-hydroxy-2- hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine,
(2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxy-prop-1-yl)pyrrolidine,
(2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(1 ,3-dihydroxy-prop-2-yl)pyrrolidine,
(2S,3S,4S)-1-(2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, preferably
(2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine.
22. The use according to claim 1 , wherein the compound of general formula (I) is (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine.
23. The use according to claim 1 , wherein the compound of general formula (I) is (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, hydrobromide or (2R,3R,4R)-3,4- dihydroxy-2-hydroxymethylpyrrolidine, hydrochloride.
24. (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, hydrobromide.
25. The use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for the treatment or prophylaxis of obesity or appetite regulation.
26. The use of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake.
27. The use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake.
28. The use of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine for the manufacture of a medicament for lowering of food intake of food with a high fat content.
29. The use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for lowering of food intake of food with a high fat content.
30. The use of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
31. The use of a glycogen phosphorylase inhibitor for the manufacture of a medicament for changing the preference of food with a high fat content to food with a low fat content.
32. A method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a compound of formula I defined in anyone of the claims 1-23 to a patient in need of such a treatment.
33. A method for the treatment or prophylaxis of obesity or appetite regulation which method comprises administering an effective amount of a glycogen phosphorylase inhibitor to a patient in need of such a treatment.
EP00903558A 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation Withdrawn EP1150674A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900188 1999-02-12
WOPCT/DK99/00188 1999-02-12
PCT/DK2000/000055 WO2000047206A1 (en) 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Publications (1)

Publication Number Publication Date
EP1150674A1 true EP1150674A1 (en) 2001-11-07

Family

ID=8090773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00903558A Withdrawn EP1150674A1 (en) 1999-02-12 2000-02-10 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation

Country Status (4)

Country Link
EP (1) EP1150674A1 (en)
JP (1) JP2002536410A (en)
AU (1) AU2535700A (en)
WO (1) WO2000047206A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1558245A2 (en) * 2002-10-28 2005-08-03 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2005041972A1 (en) * 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
SG134333A1 (en) 2003-11-12 2007-08-29 Phenomix Corp Heterocyclic boronic acid compounds
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR49M (en) * 1959-07-27 1960-11-28 Boehringer Sohn Ingelheim Crystallized salts of substituted pyrrolidines
GB8501438D0 (en) * 1985-01-21 1985-02-20 Fujisawa Pharmaceutical Co Pyrrolidine derivatives
CZ120398A3 (en) * 1995-09-08 1998-12-16 Novo Nordisk A/S Use of 2-alkylpyrrolidine derivatives for the preparation of a medicament for the treatment of diabetes, 2-alkylpyrrolidine derivatives
JPH09295966A (en) * 1996-03-04 1997-11-18 Suntory Ltd Pyrrolidine alkaloid compound
UA57811C2 (en) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Compositions including aldose reductase inhibitors and glycogen phosphorylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0047206A1 *

Also Published As

Publication number Publication date
WO2000047206A1 (en) 2000-08-17
AU2535700A (en) 2000-08-29
JP2002536410A (en) 2002-10-29

Similar Documents

Publication Publication Date Title
WO2000047206A1 (en) Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
WO2004052362A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
US5977161A (en) Kappa-opiate agonists effective in the treatment of postoperative ileus
KR20080070848A (en) Hydrazone Derivatives and Uses thereof
JP2826379B2 (en) A therapeutic agent for obesity hypertension comprising a thiazolidine derivative as an active ingredient
HU199440B (en) Process for producing morpholine derivatives and pharmaceutical compositions comprising the compounds
US6455567B1 (en) Method of treatment
JP2007509113A (en) Use of pyrazole derivatives in the preparation of medical products useful in the prevention and treatment of dyslipidemia and dyslipidemia and / or diseases associated with obesity
US5434177A (en) Imidazoles for the treatment of age-related cognitive disorders and alzheimer
AU2024203992A1 (en) Prophylactic or therapeutic agent for porphyria
JPS61286359A (en) N-((5-(trifluoromethyl)-6-methoxy-1-naphthalenyl) thioxomethyl or carbonyl)-n-methylglycineamide
JP2020019722A (en) Pharmaceutical composition for neuropathic pain
JPH03209355A (en) Use of arylalkylamide in therapy for disease of nerve denaturation
US5760065A (en) Anti-HIV agent
WO2001007023A2 (en) Azetidine compounds in cns and eye diseases
EP1977750A1 (en) Use of thioproline in body weight reduction treatments
WO2010098298A1 (en) Pharmaceutical composition comprising combination of compound having nutrient digestion/absorption inhibitory activity and cyclohexanecarboxamide derivative
RU2093149C1 (en) Pharmaceutical composition used for treatment and prophylaxis of obesity-associated hypertension
JPH04342526A (en) Peripheral circulation improver of extremity and inhibitor of blood vessel contracture
WO2025254184A1 (en) Medicine for preventing and treating disease attributable to obese condition
EA028995B1 (en) Tesofensine and optically active acetylamino acid salts, use thereof in the treatment and/or prevention of disorders related to obesity
WO2000055131A1 (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
JPH07277972A (en) Antidiabetic agent
JPS61200917A (en) Medicinal composition containing betaxolol and nifedipin
WO2000055132A1 (en) New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030716

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031101